Cover Image
市場調查報告書

全球癌症治療用單株抗體市場:成長、趨勢、預測 (2015年∼2020年)

Global Cancer Monoclonal Antibodies Market - Growth, trend, and forecast (2016-2021)

出版商 Mordor Intelligence LLP 商品編碼 353907
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
全球癌症治療用單株抗體市場:成長、趨勢、預測 (2015年∼2020年) Global Cancer Monoclonal Antibodies Market - Growth, trend, and forecast (2016-2021)
出版日期: 2016年03月01日 內容資訊: 英文
簡介

全球癌症治療用單株抗體市場,2015年達到270億美元,預計2015年∼2020年以8∼15%的年複合成長率成長。

本報告提供全球癌症治療用單株抗體市場相關調查分析,市場概要,推動市場要素、阻礙因素、機會,各市場區隔的市場分析,競爭情形,主要企業等系統性資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 主要推論

第5章 市場概要與產業趨勢

  • 目前市場方案
  • 應用
  • 技術概要
  • 新的發展
  • 產業價值鏈分析
  • 產品生命週期分析
  • 產品基準
  • 投資分析
  • 波特的五力分析

第6章 推動因素、阻礙因素、機會、課題分析

  • 推動市場要素
  • 阻礙市場要素
  • 市場課題

第7章 市場區隔

  • 各應用
  • 單株抗體的各類型
  • 使用單株抗體的複合癌症治療

第8章 市場區隔 (各地區) :各地區的佔有率與預測

  • 北美
  • 歐洲
  • 亞太地區
  • 中東、非洲
  • 南美

第9章 競爭情形

  • M&A分析
  • 專利分析
  • 課題

第10章 主要供應商分析

  • Amgen Inc.
  • Bristol-Meyer Squibb
  • GlaxoSmithKline
  • Roche Holding
  • Spectrum Pharmaceuticals
  • Merck & Co. Inc.
  • Eli Lilly & co.
  • ImmunoGen Inc.
  • Seattle Genetics
  • Janssen Biotech Inc.
  • Genmab
  • Novartis AG

第11章 投資機會預測

第12章 市場未來發展預測

目錄

The Global Cancer Monoclonal Antibodies Market was valued at USD 27 billion for the year 2015, and is expected to grow at a CAGR of around 8-15% from 2015 to 2020. Cancer is a severe disease, which starts from a single cell; cancer genetically transforms a normal cell into a tumor cell. Gradually, it spreads to more cells. There is no one definite cause for cancer. The interaction between a person's genetic factor and other external agents (physical carcinogens, such as ultraviolet and ionizing radiation, chemical carcinogens, and biological carcinogens) can roughly be cited as the major cause. In 2012, WHO reported 14 million new cancer cases and 8.2 million deaths due to cancer. The most common types of cancer that caused death are lung cancer, liver cancer, stomach cancer, colorectal cancer, breast cancer and esophageal cancer. There is a steady rise and incidence of cancer annually. Drugs haven't been able to provide complete cure for any cancer. Moreover, all these drugs available for cancer as chemotherapeutic agents have adverse side-effects because the drugs tend to affect the normal, healthy cells along with the cancerous cells. Hence, there is huge amount of research and development going on all over the world to combat this deadly disease.

Monoclonal antibodies are specifically cloned antibodies that have the capability to identify cancer cells, bind to proteins on their surface and simulate an immune response. Due to their specificity, they are expected and have been proved to lessen the adverse effects of cancer to a much higher level. Most major pharmaceutical companies are investing for research on monoclonal antibodies. The drug research companies have also collaborated with many academics and institutions like National Institutes of Health, USA, National Cancer Institute, USA and many others for research and development of cancer drugs/ monoclonal antibodies. Due to the highly customizable nature of monoclonal antibodies, various organizations, research institutes and companies are using it as a tool to target various cancers.

The global monoclonal antibody market has been segmented based on:

  • Therapeutic application
  • Breast,
  • Liver
  • Blood
  • Brain
  • Colorectal
  • Hodgkins and non-hodgkins lymphoma
  • leukemia
  • Others
  • Types of monoclonal antibodies
  • Murine antibodies
  • Chimeric and humanized antibodies
  • Fully humanized antibodies
  • Conjugated cancer therapies using monoclonal antibodies
  • Immunoliposome
  • Radioimmunotherapy
  • ADEPT
  • Immunocytokines.

Avastin, Rituxan, Bexxar, Kadcyla, Erbitux, Arzerra, Yervoy, Adcetris, Herceptin are some of the well-marketed monoclonal antibodies. A large patient population, severity of the disease, unavailability of good drugs and side effects of the existing drugs are the main reasons for the big void in the monoclonal antibodies market for new entrants to fill in. With only few monoclonal antibodies in the market exclusively for cancer therapies, there is always a good prospect for a new entrant. Conjugated therapies, using monoclonal antibodies, have been observed to give better results compared to stand alone treatment. Currently, there is a trend towards more research in conjugated therapies. With growing collaborations with institutes and companies, a very good market is expected in the near future. North America has the largest market for cancer monoclonal antibodies. India, China and Australia are expected to have a large market in the near future.

The key players in this market are Amgen, Bristol Meyer Squibb, GlaxoSmithKline, Roche, Eli Lilly, ImmunoGen, Novartis, Genmab and others.

Drivers

  • Large global patient pool
  • Severity of the disease
  • Unavailability of completely curing drugs
  • Side effects of the existing drugs
  • More specificity of monoclonal antibodies in targeting cancer cells

Challenges

  • Stringent regulatory guidelines
  • Long duration of research and development
  • Long duration of clinical trials
  • High cost for research and development

Table of Contents

1. Introduction

  • 1.1. Study deliverables
  • 1.2. Market Definition
  • 1.3. Sizing Units
  • 1.4. Base Currency
  • 1.5. Review and Forecast period years
  • 1.6. General Study Assumptions

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Analysis Methodology
  • 2.3. Econometric Forecast Model
  • 2.4. Research Assumptions

3. Executive Summary

4. Key Inferences

5. Market Overview and Industry trends

  • 5.1. Current Market Senario
  • 5.2. Cancer Monoclonal antibody Applications
  • 5.3. Technology Overview
  • 5.4. New Developments
  • 5.5. Industry Value chain analysis
  • 5.6. product Life cycle analysis
  • 5.7. Product Benchmarking
  • 5.8. Investment Analysis
  • 5.9. Porter's Five Forces
    • 5.9.1. Bargaining Power of Suppliers
    • 5.9.2. Bargaining Power of Consumers
    • 5.9.3. Threat to new entrants
    • 5.9.4. Threat to substitute products and services
    • 5.9.5. Competitive Rivalry within the industry

6. Drivers, Restraints, Opportunities, and challenges Analysis

  • 6.1. Market Drivers
    • 6.1.1. Large global patient population
    • 6.1.2. Severity of the disease with chronic nature
    • 6.1.3. Side effects of existing drugs/ therapy
    • 6.1.4. Specificity of Monoclonal antibodies
  • 6.2. Market Restraints
    • 6.2.1. Stringent Regulatory guidelines
  • 6.3. Key Challenges
    • 6.3.1. High Research and development cost
    • 6.3.2. Longer duration of R&D and Clinical Trials

7. Market Segmentation

  • 7.1. By Application
    • 7.1.1. Breast Cancer
    • 7.1.2. Non-small cell Lung cancer
    • 7.1.3. Neuroblastoma
    • 7.1.4. Melanoma
    • 7.1.5. Gastric cancer
    • 7.1.6. leukemia
    • 7.1.7. Hodgkin Lymphoma
    • 7.1.8. Malignant ascites
    • 7.1.9. Colorectal cancer
    • 7.1.10. non-Hodgkin Lymphoma
    • 7.1.11. Brain Tumor
    • 7.1.12. Lymphocytic Leukemia
    • 7.1.13. Ovarian cancer
    • 7.1.14. Others
  • 7.2. By types of Monoclonal Antibodies
    • 7.2.1. Murine Antibodies
    • 7.2.2. Chimeric and Humaized Antibodies
    • 7.2.3. Fully Humanized antibodies
  • 7.3. By Conjugated Cancer therapies using Monoclonal Antibodies
    • 7.3.1. Immunoliposomes
    • 7.3.2. Radioimmunotherapy
    • 7.3.3. Antibody directed enzyme prodrug therapy
    • 7.3.4. Immunotoxins
    • 7.3.5. Immunocytokines
    • 7.3.6. Others

8. Market segmentation by Geography - Regional Share and forecast

  • 8.1. North America
    • 8.1.1. Introduction
    • 8.1.2. United States
    • 8.1.3. Canada
    • 8.1.4. Rest of North America
  • 8.2. Europe
    • 8.2.1. Introduction
    • 8.2.2. Germany
    • 8.2.3. United Kingdom
    • 8.2.4. France
    • 8.2.5. Italy
    • 8.2.6. Spain
    • 8.2.7. Russia
    • 8.2.8. Rest of Europe
  • 8.3. Asia-Pacific (APAC)
    • 8.3.1. Introduction
    • 8.3.2. China
    • 8.3.3. Japan
    • 8.3.4. India
    • 8.3.5. Australia
    • 8.3.6. South Korea
    • 8.3.7. Rest of Asia Pacific
  • 8.4. Middle-East and Africa
    • 8.4.1. Introduction
    • 8.4.2. UAE
    • 8.4.3. Saudi Arabia
    • 8.4.4. Israel
    • 8.4.5. Rest of Middle-east & Africa
  • 8.5. Latin America
    • 8.5.1. Introduction
    • 8.5.2. Brazil
    • 8.5.3. Argentina
    • 8.5.4. Mexico
    • 8.5.5. Rest of Latin America

9. Competitive Landscape

  • 9.1. Merger and acquisition analysis
  • 9.2. Patent Analysis
  • 9.3. The Challenges

10. Key Vendor Analysis

  • 10.1. Amgen Inc.
  • 10.2. Bristol-Meyer Squibb
  • 10.3. GlaxoSmithKline
  • 10.4. Roche Holding
  • 10.5. Spectrum Pharmaceuticals
  • 10.6. Merck & Co. Inc.
  • 10.7. Eli Lilly & co.
  • 10.8. ImmunoGen Inc.,
  • 10.9. Seattle Genetics
  • 10.10. Janssen Biotech Inc.
  • 10.11. Genmab
  • 10.12. Novartis AG

11. Analyst outlook for Investment opportunities

12. Future Outlook of the market

Back to Top